JTCS Medtronic Endurant
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Guldner, N. W.
Right arrow Articles by Sievers, H. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Guldner, N. W.
Right arrow Articles by Sievers, H. H.
Related Collections
Right arrow Valve disease

J Thorac Cardiovasc Surg 2009;138:248-250
© 2009 The American Association for Thoracic Surgery

Brief Research Report

The first self-endothelialized titanium-coated glutaraldehyde-fixed heart valve prosthesis within systemic circulation

Norbert W. Guldner, MDa,*, Inka Jasmund, MSa, Hanngörg Zimmermann, MSb, Markus Heinlein, MSb, Britta Girndt, MSb, Martin Großherr, MDc, Mathias Klinger, MDd, Hans H. Sievers, MDa

a Klinik für Herzchirurgie, UK-SH Campus Lübeck, Lübeck, Germany
b GfE Medizintechnik GmbH, Nürnberg, Germany
c Klinik und Institut für Anästhesiologie, Universität zu Lübeck, Lübeck, Germany
d Institut für Anatomie, Universität zu Lübeck, Lübeck, Germany

Received for publication September 30, 2008; revisions received November 5, 2008; accepted for publication November 24, 2008.

* Address for reprints: Norbert W. Guldner, MD, Klinik für Herzchirurgie, Universitätsklinikum Schleswig-Holstein, Campus Lübeck, Ratzeburger Allee 160, D- 23538 Lübeck, Germany. (Email: guldner@uni-luebeck.de).

The first 20% of the full text of this article appears below.


   Introduction
 
At present, 275 000 heart valve replacements are performed annually world wide. Roughly 60% are glutaraldehyde-fixed tissue valve prostheses. Glutaraldehyde-fixed tissues such as bovine pericardium and porcine heart valves are the commonly used base materials for the construction of bioprosthetic heart valves as substitutes in humans. However, premature degradation limits valve durability, especially in younger patients. Cell-coated blood-contacting surfaces of glutaraldehyde-fixed biological heart valves are hypothesized to improve biocompatibility and durability.1Go The toxicity of glutaraldehyde, however, prevents biological coating if not partially detoxified and preseeded by fibroblasts followed by endothelial cell seeding in vitro.1Go

Titanium has proven itself to be the leading structured metallic biomaterial for 50 years.2Go Theoretically, surface coating of the less biocompatible glutaraldehyde-treated tissue with titanium may open new avenues for improving biocompatibility. However, a titanium coating on biomaterials seemed not to be possible until now owing to the high temperatures needed for commonly used sputtering techniques. Therefore, a coating method was applied for a biological substrate, using a plasma-activated chemical vapor deposition with the . . . [Full Text of this Article]




This article has been cited by other articles:


Home page
 Asian Cardiovasc. Thorac. Ann.Home page
N. W Guldner, P. Klapproth, P. R. Margaritoff, R. Noel, H. H Sievers, and M. Grossherr
Impact of Valves in a Biomechanical Heart Model Assisting Failing Hearts
Asian Cardiovasc Thorac Ann, December 1, 2009; 17(6): 592 - 597.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 2009 by The American Association for Thoracic Surgery.